In vitro-in vivo correlation for intrinsic clearance for drugs metabolized by human aldehyde oxidase

Drug Metabolism and Disposition

Volumn 38, Issue 8, 2010, Pages 1322-1327

  Zientek, Michael ^a   Jiang, Ying ^a   Youdim, Kuresh ^b   Obach, R Scott ^a  

^a PFIZER INC   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 CYANOANILINO) 6,7 DIHYDRO 7 HYDROXY 5H CYCLOPENTA[D]PYRIMIDINE; 6 DEOXYPENCICLOVIR; 6 O BENZYLGUANINE; ALDEHYDE OXIDASE; CARBAZERAN; METHOTREXATE; N (2 DIMETHYLAMINOETHYL) 4 ACRIDINECARBOXAMIDE; PF 4217903; PF 945863; UNCLASSIFIED DRUG; XK 469; ZALEPLON; ZONIPORIDE;

ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENZYME METABOLISM; HUMAN; LIVER CYTOSOL; PRIORITY JOURNAL;

ALDEHYDE OXIDASE; CYTOSOL; HUMANS; LIVER; PHARMACEUTICAL PREPARATIONS; PROTEIN BINDING;

ANIMALIA; CANIS FAMILIARIS; RATTUS;

EID: 77954897164     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.033555     Document Type: Article

References (23)

1. Alousi AM, Boinpally R, Wiegand R, Parchment R, Gadgeel S, Heilbrun LK, Wozniak AJ, DeLuca P, and LoRusso PM (2007) A phase 1 trial of XK469: toxicity profile of a selective topoisomerase IIbeta inhibitor. Invest New Drugs 25:147-154.
2. Beedham C (2001) Molybdenum hydroxylases, in Enzyme Systems That Metabolise Drugs and Other Xenobiotics (Ioannides C ed), pp 147-187, John Wiley & Sons, Ltd., Chichester, West Sussex, UK.
3. Beedham C, Miceli JJ, and Obach RS (2003) Ziprasidone metabolism, aldehyde oxidase, and clinical implications. J Clin Psychopharmacol 23:229-232.
4. Dalvie D, Zhang C, Chen W, Smolarek T, Obach RS, and Loi CM (2010) Cross-species comparison of the metabolism and excretion of zoniporide: contribution of aldehyde oxidase to interspecies differences. Drug Metab Dispos 38:641-654.
5. Dolan ME, Roy SK, Fasanmade AA, Paras PR, Schilsky RL, and Ratain MJ (1998) O6-benzylguanine in humans: metabolic, pharmacokinetic, and pharmacodynamic findings. J Clin Oncol 16:1803-1810.
6. Duley JA, Harris O, and Holmes RS (1985) Analysis of human alcohol- and aldehyde-metabolizing isozymes by electrophoresis and isoelectric focusing. Alcohol Clin Exp Res 9:263-271. (Pubitemid 15011403)
7. Filer CW, Allen GD, Brown TA, Fowles SE, Hollis FJ, Mort EE, Prince WT, and Ramji JV (1994) Metabolic and pharmacokinetic studies following oral administration of 14C-famciclovir to healthy subjects. Xenobiotica 24:357-368.
8. Garattini E, Fratelli M, and Terao M (2008) Mammalian aldehyde oxidases: genetics, evolution and biochemistry. Cell Mol Life Sci 65:1019-1048.
9. Houston JB and Galetin A (2008) Methods for predicting in vivo pharmacokinetics using data from in vitro assays. Curr Drug Metab 9:940-951.
10. Johns DG (1967) Human liver aldehyde oxidase: differential inhibition of oxidation of charged and uncharged substrates. J Clin Invest 46:1492-1505.
11. Johnson C, Stubley-Beedham C, and Stell JG (1985) Hydralazine: a potent inhibitor of aldehyde oxidase activity in vitro and in vivo. Biochem Pharmacol 34:4251-4256.
12. Kaye B, Offerman JL, Reid JL, Elliott HL, and Hillis WS (1984) A species difference in the presystemic metabolism of carbazeran in dog and man. Xenobiotica 14:935-945.
13. Kestell P, Dunlop IC, McCrystal MR, Evans BD, Paxton JW, Gamage RS, and Baguley BC (1999) Plasma pharmacokinetics of N-[2-(dimethylamino)ethyl]acridine- 4-carboxamide in a phase I trial. Cancer Chemother Pharmacol 44:45-50.
14. Kilford PJ, Stringer R, Sohal B, Houston JB, and Galetin A (2009) Prediction of drug clearance by glucuronidation from in vitro data: use of combined cytochrome P450 and UDP-glucuronosyltransferase cofactors in alamethicin-activated human liver microsomes. Drug Metab Dispos 37:82-89.
15. Kristensen LO, Weismann K, and Hutters L (1975) Renal function and the rate of disappearance of methotrexate from serum. Eur J Clin Pharmacol 8:439-444.
16. Lake BG, Ball SE, Kao J, Renwick AB, Price RJ, and Scatina JA (2002) Metabolism of zaleplon by human liver: evidence for involvement of aldehyde oxidase. Xenobiotica 32:835-847.
17. Obach RS (2001) The prediction of human clearance from hepatic microsomal metabolism data. Curr Opin Drug Discov Devel 4:36-44.
18. Obach RS (2004) Potent inhibition of human liver aldehyde oxidase by raloxifene. Drug Metab Dispos 32:89-97.
19. Puchler K, Sasahara K, Plenker A, Nitanai T, and Witte PU (1997) The pharmacokinetic profile of RS-8359. Int Clin Psychopharmacol 5 (Suppl 12):S11-S16.
20. Rashidi MR, Smith JA, Clarke SE, and Beedham C (1997) In vitro oxidation of famciclovir and 6-deoxypenciclovir by aldehyde oxidase from human, guinea pig, rabbit, and rat liver. Drug Metab Dispos 25:805-813.
21. Rosen AS, Fournié P, Darwish M, Danjou P, and Troy SM (1999) Zaleplon pharmacokinetics and absolute bioavailability. Biopharm Drug Dispos 20:171-175.
22. Seideman P (1993) Methotrexate-the relationship between dose and clinical effect. Br J Rheumatol 32:751-753.
23. Zhang H, Davis CD, Sinz MW, and Rodrigues AD (2007) Cytochrome P450 reaction-phenotyping: an industrial perspective. Expert Opin Drug Metab Toxicol 3:667-687.